Methotrexat Ebewe

Methotrexate, the active ingredient in Methotrexat Ebewe, is an Antimetabolite (Folate antagonist) presented as a sterile injectable solution for intra‑arterial, intramuscular, and intrathecal use. It is employed to treat rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma and breast cancer in appropriate patients.

GNH USA supplies Methotrexat Ebewe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use. Our distribution network ensures timely delivery across multiple continents.

Methotrexate is used in several disease categories where inhibition of folate metabolism modifies disease activity.

- Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: decreases skin cell proliferation, leading to clearance of plaques. - Acute lymphoblastic leukemia: interferes with malignant cell replication, contributing to remission. - Non‑Hodgkin lymphoma: impairs tumor growth by blocking DNA synthesis in lymphoid cells. - Breast cancer: used in combination regimens to inhibit tumor cell division.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting - Fatigue - Mouth sores - Low blood cell counts - Elevated liver enzymes

Serious or Rare Side Effects: - Severe bone marrow suppression - Pulmonary fibrosis - Hepatotoxicity leading to cirrhosis - Renal failure - Life‑threatening infections

When prescribing methotrexate, clinicians should observe several safety measures to minimize risk.

- Baseline testing: obtain complete blood count, liver and renal function before initiation. - Monitoring: perform regular laboratory assessments to detect hematologic or hepatic toxicity. - Contraindications: avoid use in patients with severe hepatic disease or active infections. - Pregnancy: contraindicated in pregnancy; ensure effective contraception for women of child‑bearing potential. - Drug interactions: review concomitant medications that may increase toxicity, such as NSAIDs or penicillins. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Methotrexate interacts with several agents that can alter its efficacy or increase toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can raise methotrexate serum levels and risk renal toxicity. - Proton pump inhibitors: may reduce renal clearance, enhancing toxicity. - Trimethoprim‑sulfamethoxazole: potentiates bone marrow suppression.

Moderate Interactions (Monitor Closely): - Azathioprine or other immunosuppressants: additive immunosuppression may increase infection risk. - Live vaccines: reduced efficacy and potential for infection. - Alcohol: can exacerbate hepatotoxicity.